Approved indications: Fabhalta is approved for adults to treat paroxysmal nocturnal hemoglobinuria (PNH) and to reduce protein in the urine (proteinuria) in adults with primary IgA nephropathy at risk of rapid disease progression and in adults with complement 3 glomerulopathy (C3G).

Off-label uses: Because Fabhalta is a relatively new, highly targeted therapy, there are no well-established off-label uses; outside its approved indications it is generally used only in clinical trials or under specialist supervision for other complement-mediated diseases.

Efficacy in PNH: In clinical studies, most adults with PNH who switched from anti-C5 infusions to Fabhalta had meaningful hemoglobin increases (often at least 2 g/dL) without needing transfusions, with improvements often beginning within the first few weeks and maintained over at least 6–12 months.

Efficacy in IgA nephropathy and C3G: In primary IgA nephropathy and C3G, Fabhalta reduced proteinuria on average by roughly one-third to one-half over about 6–9 months, with longer-term data showing sustained proteinuria reductions and, in IgA nephropathy, a slowing of kidney function decline over approximately two years.

Comparison to other therapies: Compared with older complement inhibitors that require regular IV or subcutaneous infusions, Fabhalta offers similar or superior control of hemolysis in PNH as an oral capsule, and in kidney diseases it adds a targeted alternative-complement inhibitor to existing proteinuria-lowering therapies such as renin–angiotensin system blockers, SGLT2 inhibitors, and endothelin receptor antagonists.

Typical dosing: For all approved adult indications, the recommended dose is 200 mg (one capsule) taken by mouth twice daily, about 12 hours apart, with or without food; capsules should be swallowed whole and not opened, broken, or chewed.

Before and during treatment: Vaccination against meningococcal and pneumococcal bacteria (and often Haemophilus influenzae type b) is required at least 2 weeks before starting when possible, and if you are switching from an IV complement inhibitor such as eculizumab (Soliris) or ravulizumab (Ultomiris), your doctor will time the first Fabhalta dose within about 1 week or 6 weeks of the last infusion, respectively, to avoid rebound hemolysis; no routine dose adjustments are needed for mild to moderate kidney or liver impairment, but the drug is generally avoided in severe impairment.

How to take it: Take Fabhalta at the same times each morning and evening to help keep levels steady, with a glass of water, and avoid crushing or sprinkling the capsule contents on food.

Missed doses: If you miss one or more doses, take a single 200 mg capsule as soon as you remember, even if it is close to the next scheduled dose, then return to your usual twice-daily schedule without taking extra capsules to make up for missed doses.

Overdose: In case of accidental overdose, contact a poison control center or emergency medical services right away; your care team will monitor for side effects such as infections, gastrointestinal symptoms, or laboratory changes and provide supportive treatment as needed.

Common side effects: The most frequently reported problems include headache, nasal or throat symptoms (such as congestion, runny nose, cough, sneezing, or sore throat), diarrhea, stomach (abdominal) pain, nausea, rash, and mild viral or bacterial infections; these are usually mild to moderate in severity and often appear in the first weeks to months of treatment.

Serious risks: Fabhalta can increase the risk of serious or life-threatening infections caused by encapsulated bacteria (including meningococcal, pneumococcal, and Haemophilus influenzae type b), and may also trigger rapid worsening of PNH or kidney disease if doses are missed or the medicine is stopped abruptly; symptoms such as high fever, severe headache, stiff neck, confusion, chest pain, shortness of breath, blood in the urine, or signs of blood clots require immediate medical attention.

Warnings and precautions: Because of its infection risk, Fabhalta is available only through a REMS program and requires vaccination against certain encapsulated bacteria before starting, with antibiotic prophylaxis if treatment must begin before vaccines take full effect; it is not recommended for people with severe kidney failure (eGFR <30 mL/min/1.73 m²) or severe liver impairment, has limited data in older adults, and is not established for use in children.

Pregnancy and breastfeeding: Information in pregnancy is limited, so use is considered only when potential benefits outweigh risks from both the disease and the drug, and people who can become pregnant should discuss reliable birth control while on therapy; breastfeeding is not recommended during treatment or for 5 days after the last dose because it is unknown whether the medicine passes into human milk or affects a nursing infant.

Safety compared with similar drugs: Like other complement inhibitors, Fabhalta carries a class-wide risk of severe bacterial infections but avoids infusion reactions and injection-site problems seen with IV or injectable agents; clinicians generally monitor patients with periodic blood counts, kidney function tests, and cholesterol and triglyceride levels because Fabhalta can increase blood lipids.

Side-effect reporting and safety updates: Patients should promptly tell their prescriber or pharmacist about any bothersome or persistent side effects and can report serious problems through the FDA’s MedWatch program by phone or online; updated safety information is reflected in the Medication Guide and official prescribing information used by clinicians.

Prescription and OTC medicines: Fabhalta is metabolized mainly by the liver enzyme CYP2C8, so strong CYP2C8 inducers (such as rifampin) can lower its levels and reduce benefit, while strong CYP2C8 inhibitors (such as gemfibrozil) can raise its levels and increase side-effect risk; taking Fabhalta with a strong CYP2C8 inhibitor is generally not recommended, and all other prescription, over-the-counter, and herbal medicines should be reviewed with your prescriber.

Supplements, alcohol, and vaccines: No specific food or alcohol restrictions are built into the prescribing information, but heavy alcohol use may worsen liver or kidney problems, so moderation is advised; because Fabhalta weakens part of the immune system, combining it with other potent immunosuppressants or failing to keep up with recommended vaccines can further increase infection risk, so vaccination schedules and any other immune-modifying drugs should be carefully coordinated by your specialist.

Medical conditions requiring caution: Use requires special care in people with current infections or fever, a history of serious infections from encapsulated bacteria, severe renal or hepatic impairment, and in pregnant patients, and it is not approved for use in children; if Fabhalta must be stopped, clinicians monitor closely for at least 2 weeks for signs of renewed hemolysis or kidney disease flare.

Monitoring needs: Typical monitoring includes regular blood counts and markers of hemolysis in PNH, kidney function and urine protein tests in IgA nephropathy and C3G, lipid panels to check for increased cholesterol and triglycerides, and ongoing assessment for early symptoms of serious infection.

Q: How long does it take for Fabhalta to start working?
A: Some people with PNH notice more energy and better blood counts within a few weeks, while kidney conditions like IgA nephropathy and C3G usually require several months of continuous treatment before protein in the urine falls significantly.

Q: Why do I need vaccines before starting Fabhalta?
A: Fabhalta blocks part of the complement system that helps fight certain bacteria, so vaccines against meningococcal, pneumococcal, and often Haemophilus influenzae type b infections are used to lower the chance of severe, life-threatening infections while you are on the medicine.

Q: What should I do if I miss a dose of Fabhalta?
A: Take one 200 mg capsule as soon as you remember, even if it is close to your next scheduled time, then continue your regular twice-daily dosing without taking extra capsules to make up for missed doses.

Q: Can I stop Fabhalta if I feel better?
A: Do not stop Fabhalta or change your dose on your own, because sudden interruption can cause rapid breakdown of red blood cells in PNH or worsening kidney disease; your doctor will adjust or stop it only with close monitoring and a plan for follow-up labs and symptoms.

Q: Is Fabhalta safe in pregnancy or while breastfeeding?
A: There is limited information about Fabhalta in pregnancy, so decisions are individualized based on the risks of the underlying disease and potential drug effects, and breastfeeding is generally avoided during treatment and for 5 days after the last dose.

Q: Does Fabhalta interact with my other medicines?
A: Certain drugs that strongly affect the CYP2C8 enzyme, such as rifampin or gemfibrozil, can change Fabhalta levels, so your healthcare team should review all of your prescriptions, over-the-counter medicines, and supplements before you start and throughout treatment.

Storage: Store Fabhalta capsules at room temperature (68–77°F or 20–25°C), in a dry place away from excess heat and light; do not refrigerate or freeze, and keep the original container or blister pack tightly closed and out of reach of children and pets.

Disposal: When capsules are expired or no longer needed, use a community medicine take-back program if available; if not, ask a pharmacist how to dispose of them safely and do not flush them down the toilet or pour them down a drain unless specifically instructed.